Key facts
- It has raised $44.9M; the latest was Later Stage VC in Dec 2024.
- Notable investors include GL Ventures, Legend Star, YuanBio Venture Capital, Sinovation Ventures, Guangzhou Yuexiu Industrial Investment Fund Management — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Reforgene Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Reforgene Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reforgene Medicine
Developer of new drugs intended to cure genetic diseases, chronic diseases and cancer. The company develops programmable medicine based on genome editing technologies, enabling patients to have better treatment and get cured.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2019
- Website
- reforgene.com/
- Ownership
- Privately Held (backing)
Reforgene Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reforgene Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reforgene Medicine in its N-PORT filings yet. We sweep new filings monthly.